Results from GSEA report show that oncogenic signatures such as KRAS, MEK, AKT, and MTOR signaling targets and transcription factors targets (e.g., ATF, E2F) were positively enriched in KRAS mutant CRC cells (Table S3). The gene discussed is KRAS; the disease is colorectal carcinoma.